Med. praxi. 2023;20(1):17-24 | DOI: 10.36290/med.2023.002

Chronic venous disease and cardiovascular disease

doc. MUDr. Debora Karetová, CSc.1, prof. MUDr. Jan Bultas, CSc.2
1 II. interní klinika - klinika kardiologie a angiologie 1. LF UK a VFN, Praha
2 Farmakologický ústav 3. LF UK, Praha

Chronic venous disease (CVD) and cardiovascular (CV) disease have a high prevalence worldwide. A number of studies suggest the possibility of a correlation between these two diseases of an unclear etiology. The effects of altered hemodynamics in right ventricular dysfunction with subsequent elevation of venous pressure may undoubtedly cause symptoms and signs typical of chronic venous disease. There are also some common risk factors for both diseases: especially obesity and metabolic syndrome. However, chronic inflammation causing alteration of endothelial function could also be a common denominator. The Gutenberg Health Study, an epidemiological study conducted at the University of Mainz, investigated the risk factors for CVD and CV disease. Cross-sectional analysis of the general population aged between 40 and 80 years confirmed a high prevalence of CVD, with 36.5% of those examined. The main determinants of chronic venous insufficiency (CVI) were age, female sex, arterial hypertension, obesity, smoking and any cardiovascular disease. Chronic venous insufficiency, an advanced stage of venous disease, was associated with a prediction of increased 10-year mortality in persons without manifest cardiovascular disease. During a follow-up of 6.4 years (±1.6), the the presence of CVI was verified to be a strong predictor of overall mortality, irrespective of the clinical profile of the patient and concomitant medication.

Keywords: chronic venous disease, cardiovascular disease, atherosclerosis, Gutenberg Health Study.

Accepted: March 2, 2023; Published: March 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karetová D, Bultas J. Chronic venous disease and cardiovascular disease. Med. praxi. 2023;20(1):17-24. doi: 10.36290/med.2023.002.
Download citation

References

  1. Castro­‑Ferreira R, Cardoso R, Leite­‑Moreira A, et al. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380-393. Go to original source...
  2. Lattimer CR, Kalodiki E, Geroulakos G, et al. Are inflammatory biomarkers increased in varicose vein blood? Clin Appl Thromb Hemost. 2016;22:656-664. Go to original source...
  3. Marchio P, Guerra­‑Ojeda S, Vila JM, et al. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2019 Jul 1;2019:8563845. Go to original source...
  4. Sanz M, Del Castillo AM, Jepsen S, et al. Periodontitis and Cardiovascular Diseases. Consensus Report. Glob Heart. 2020;15(1):1. Go to original source...
  5. Dietrich T, Sharma P, Walter C, et al. The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. Journal of Clinical Periodontology. 2013;40:S70-84. Go to original source...
  6. Garshick MS, Ward NL, Krueger JG, et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670-1680. Go to original source...
  7. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-50. Go to original source... Go to PubMed...
  8. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. PMID: 28845751. Go to original source... Go to PubMed...
  9. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low­‑Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PMID: 31733140. Go to original source... Go to PubMed...
  10. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low­‑dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012. 10. 027. Epub 2012 Dec 19. PMID: 23265346. Go to original source...
  11. Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. PMID: 32865380. Go to original source... Go to PubMed...
  12. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020 May;8(3):342-352. doi: 10.1016/j.jvsv.2019. 12. 075. Epub 2020 Feb 27. Erratum in: J Vasc Surg Venous Lymphat Disord. 2021 Jan;9(1):288. PMID: 32113854. Go to original source... Go to PubMed...
  13. Tisato V, Zauli G, Voltan R, et al. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro­‑inflammatory phenotype. PLoS One. 2012;7(6):e39543. doi: 10.1371/journal.pone.0039543. Epub 2012 Jun 21. PMID: 22737245; PMCID: PMC3380919. Go to original source... Go to PubMed...
  14. Burnand KG, Whimster I, Clemenson G, et al. The relationship between the number of capillaries in the skin of the venous ulcer­‑bearing area of the lower leg and the fall in foot vein pressure during exercise. Br J Surg. 1981 May;68(5):297-300. doi: 10.1002/bjs.1800680502. PMID: 7225749. Go to original source... Go to PubMed...
  15. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17:121. Go to original source... Go to PubMed...
  16. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9: 1057-69. Go to original source...
  17. Reka IE, Imre M. Socio­‑demographic Characteristics of Patients Diagnosed with Advanced Chronic Venous Insufficiency (C4-C6) Correlated with Clinical and Para­‑clinical Findings. Acta Marisiensis Ser Medica. 2015;61:94-9. Go to original source...
  18. Singer AJ, Tassiopoulos A, Kirsner RS. Evaluation and Management of Lower­‑Extremity Ulcers. N Engl J Med. 2017;377:1559-67. Go to original source...
  19. Fiordaliso F, Clerici G, Maggioni S, et al. Prospective study on microangiopathy in type 2 diabetic foot ulcer. Diabetologia. 2016;59:1542-8. Go to original source...
  20. Saxton SN, Clark BJ, Withers SB, et al. Mechanistic Links Between Obesity, Diabetes, and Blood Pressure: Role of Perivascular Adipose Tissue. Physiol Rev. 2019;99:1701-63. Go to original source... Go to PubMed...
  21. Prochaska JH, Arnold N, Falcke A, et al. Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. Eur Heart J. 2021 Oct 21;42(40):4157-4165. doi: 10.1093/eurheartj/ehab495. PMID: 34387673. Go to original source... Go to PubMed...
  22. Karetová D, et al. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře - chronické žilní onemocnění. Novelizace 2021. SVL ČLS JEP.
  23. Nicolaides AN. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol. 2018 June; 37(3):181-254. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.